IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.68 Million USD | -2.8% |
| 2022 | -8.63 Million USD | -22.63% |
| 2021 | -7.03 Million USD | -37.8% |
| 2020 | -5.1 Million USD | 41.52% |
| 2019 | -8.73 Million USD | -5.65% |
| 2018 | -8.27 Million USD | -373.27% |
| 2017 | -1.75 Million USD | -274.89% |
| 2016 | -470 Thousand USD | -129.4% |
| 2015 | 1.58 Million USD | 192.91% |
| 2014 | -1.7 Million USD | -8.87% |
| 2013 | -1.56 Million USD | 27.45% |
| 2012 | -2.22 Million USD | 10.34% |
| 2011 | -2.6 Million USD | 18.56% |
| 2010 | -3.13 Million USD | -138.22% |
| 2009 | -1.24 Million USD | 41.98% |
| 2008 | -2.44 Million USD | -272.8% |
| 2007 | -948.17 Thousand USD | 25.81% |
| 2006 | -731.52 Thousand USD | -7710.58% |
| 2005 | -146.53 Thousand USD | -31.29% |
| 2004 | -7545.00 USD | -6886.11% |
| 2003 | -108.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.23 Million USD | -380.67% |
| 2023 Q2 | -2.32 Million USD | 3.73% |
| 2023 Q3 | -2.75 Million USD | -18.77% |
| 2023 FY | - USD | -2.8% |
| 2023 Q4 | -1.79 Million USD | 35.05% |
| 2023 Q1 | -2.41 Million USD | -3.3% |
| 2022 Q1 | -2.11 Million USD | 8.29% |
| 2022 FY | - USD | -22.63% |
| 2022 Q2 | -1.98 Million USD | 5.96% |
| 2022 Q3 | -2.19 Million USD | -10.36% |
| 2022 Q4 | -2.33 Million USD | -6.47% |
| 2021 Q1 | -1.73 Million USD | -128.89% |
| 2021 FY | - USD | -37.8% |
| 2021 Q2 | -1.55 Million USD | 10.2% |
| 2021 Q4 | -2.3 Million USD | -59.96% |
| 2021 Q3 | -1.44 Million USD | 7.51% |
| 2020 Q4 | -758 Thousand USD | 37.04% |
| 2020 Q3 | -1.2 Million USD | -2.47% |
| 2020 Q1 | -1.97 Million USD | 8.75% |
| 2020 FY | - USD | 41.52% |
| 2020 Q2 | -1.17 Million USD | 40.39% |
| 2019 Q1 | -2.11 Million USD | -4.9% |
| 2019 Q4 | -2.16 Million USD | 6.98% |
| 2019 Q3 | -2.32 Million USD | -8.81% |
| 2019 Q2 | -2.13 Million USD | -0.71% |
| 2019 FY | - USD | -5.65% |
| 2018 Q3 | -2.46 Million USD | -26.74% |
| 2018 Q2 | -1.94 Million USD | -5.82% |
| 2018 Q1 | -1.83 Million USD | -186.74% |
| 2018 FY | - USD | -373.27% |
| 2018 Q4 | -2.02 Million USD | 18.05% |
| 2017 Q4 | -641 Thousand USD | -69.13% |
| 2017 FY | - USD | -274.89% |
| 2017 Q3 | -379 Thousand USD | 14.25% |
| 2017 Q2 | -442 Thousand USD | -55.09% |
| 2017 Q1 | -285 Thousand USD | -148.89% |
| 2016 Q2 | -694 Thousand USD | -12.12% |
| 2016 Q4 | 583 Thousand USD | 120.83% |
| 2016 FY | - USD | -129.4% |
| 2016 Q3 | 264 Thousand USD | 138.04% |
| 2016 Q1 | -619 Thousand USD | -250.24% |
| 2015 FY | - USD | 192.91% |
| 2015 Q4 | 412 Thousand USD | -70.01% |
| 2015 Q2 | -242 Thousand USD | -690.24% |
| 2015 Q1 | 41 Thousand USD | 116.8% |
| 2015 Q3 | 1.37 Million USD | 667.77% |
| 2014 Q2 | -608 Thousand USD | -42.72% |
| 2014 FY | - USD | -8.87% |
| 2014 Q4 | -244 Thousand USD | 42.99% |
| 2014 Q3 | -428 Thousand USD | 29.61% |
| 2014 Q1 | -426 Thousand USD | 31.73% |
| 2013 Q4 | -624 Thousand USD | -7.22% |
| 2013 FY | - USD | 27.45% |
| 2013 Q3 | -582 Thousand USD | -654.29% |
| 2013 Q2 | 105 Thousand USD | 122.53% |
| 2013 Q1 | -466 Thousand USD | -41.21% |
| 2012 Q3 | -638 Thousand USD | 4.06% |
| 2012 Q4 | -330 Thousand USD | 48.28% |
| 2012 FY | - USD | 10.34% |
| 2012 Q1 | -477 Thousand USD | 21.16% |
| 2012 Q2 | -665 Thousand USD | -39.41% |
| 2011 Q1 | -592 Thousand USD | 41.09% |
| 2011 Q2 | -520 Thousand USD | 12.16% |
| 2011 Q4 | -605 Thousand USD | 12.57% |
| 2011 Q3 | -692 Thousand USD | -33.08% |
| 2011 FY | - USD | 18.56% |
| 2010 Q2 | -932 Thousand USD | -22.31% |
| 2010 Q1 | -762 Thousand USD | -39.15% |
| 2010 FY | - USD | -138.22% |
| 2010 Q3 | -255 Thousand USD | 72.64% |
| 2010 Q4 | -1 Million USD | -294.12% |
| 2009 Q2 | 57 Thousand USD | 112.61% |
| 2009 Q3 | -298.9 Thousand USD | -624.39% |
| 2009 Q1 | -452.2 Thousand USD | -411.57% |
| 2009 FY | - USD | 41.98% |
| 2009 Q4 | -547.6 Thousand USD | -83.21% |
| 2008 Q4 | -88.39 Thousand USD | 90.13% |
| 2008 Q1 | -473.4 Thousand USD | -686.81% |
| 2008 Q2 | -849.33 Thousand USD | -79.41% |
| 2008 Q3 | -895.28 Thousand USD | -5.41% |
| 2008 FY | - USD | -272.8% |
| 2007 Q2 | -16.71 Thousand USD | 85.5% |
| 2007 Q3 | -423.02 Thousand USD | -2431.55% |
| 2007 Q4 | 80.67 Thousand USD | 119.07% |
| 2007 FY | - USD | 25.81% |
| 2007 Q1 | -115.22 Thousand USD | 74.84% |
| 2006 Q3 | -235.39 Thousand USD | -200.17% |
| 2006 Q4 | -457.86 Thousand USD | -94.51% |
| 2006 FY | - USD | -7710.58% |
| 2006 Q1 | -1238.00 USD | 52.11% |
| 2006 Q2 | -78.42 Thousand USD | -6234.57% |
| 2005 Q1 | -3542.00 USD | -104.03% |
| 2005 Q3 | -1884.00 USD | 0.58% |
| 2005 FY | - USD | -31.29% |
| 2005 Q4 | -2585.00 USD | -37.21% |
| 2005 Q2 | -1895.00 USD | 46.5% |
| 2004 Q3 | -2746.00 USD | 10.35% |
| 2004 Q4 | -1736.00 USD | 36.78% |
| 2004 FY | - USD | -6886.11% |
| 2004 Q2 | -3063.00 USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -97.847% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 55.757% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1557.057% |
| Rebus Holdings, Inc. | -951 Thousand USD | -708.097% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 108.172% |
| Qrons Inc. | -40.08 Thousand USD | -19073.673% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1115.2% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 86.113% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1992.745% |
| Skye Bioscience, Inc. | -13.54 Million USD | 43.274% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 89.182% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -29.619% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3113.464% |
| SQZ Biotechnologies Company | -64.14 Million USD | 88.019% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -190.609% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -400.31% |
| Mesoblast Limited | -62.38 Million USD | 87.682% |
| Marizyme, Inc. | -34.28 Million USD | 77.583% |
| Genus plc | 73.7 Million USD | 110.427% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -16.237% |
| Pharming Group N.V. | 9.87 Million USD | 177.807% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -416.669% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -116.662% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 12.392% |
| ContraFect Corporation | -64.99 Million USD | 88.177% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -69.789% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -448.221% |
| IMV Inc. | -35.52 Million USD | 78.366% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -230.705% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1383.459% |
| ONE Bio Corp. | 13.61 Million USD | 156.453% |
| Accustem Sciences Inc. | -3.74 Million USD | -105.129% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 84.065% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -506.488% |
| Q BioMed Inc. | -617.62 Thousand USD | -1144.276% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 315.146% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -236.399% |
| Biomind Labs Inc. | -1.03 Million USD | -642.836% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 80.611% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -165.703% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -7.313% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 114392.088% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -30640.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 51.574% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -207.159% |
| GB Sciences, Inc. | -1.41 Million USD | -441.241% |
| Alpha Cognition Inc. | -9.7 Million USD | 20.819% |
| HST Global, Inc. | -5303.00 USD | -144817.971% |
| CSL Limited | 4.78 Billion USD | 100.16% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -273.602% |
| Halberd Corporation | -74.27 Thousand USD | -10246.127% |
| Enzolytics Inc. | -2.12 Million USD | -262.153% |
| Agentix Corp. | -1.37 Million USD | -460.231% |
| Resverlogix Corp. | -11.74 Million USD | 34.551% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -150.897% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 96.443% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 731.471% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 186.799% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -412.707% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2128.539% |
| AVAX Technologies, Inc. | -6.11 Million USD | -25.723% |
| Zenith Capital Corp. | -8.6 Million USD | 10.702% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.91% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44013.426% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -214.127% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -4265.873% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -300.071% |
| Kadimastem Ltd | -2.62 Million USD | -192.831% |
| Helix BioMedix, Inc. | -1.04 Million USD | -634.485% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -339.143% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1.739% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -4143.793% |
| LadRx Corporation | 412.28 Thousand USD | 1964.011% |
| Cell Source, Inc. | -4.27 Million USD | -79.87% |
| Regen BioPharma, Inc. | 1.46 Million USD | 624.231% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -720.215% |
| NovAccess Global Inc. | -1.03 Million USD | -642.658% |
| Affymax, Inc. | -14.29 Million USD | 46.24% |
| Itoco Inc. | -1.86 Million USD | -311.184% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1924.393% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -588.62% |
| Mobile Lads Corp. | -2.24 Million USD | -242.903% |
| CytoDyn Inc. | -18.02 Million USD | 57.374% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -9624.278% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -62742.424% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1482.324% |
| SYBLEU INC | -141.57 Thousand USD | -5328.372% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -623.628% |
| International Stem Cell Corporation | 202 Thousand USD | 3904.455% |
| Bioxytran, Inc. | -3.82 Million USD | -101.17% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14499.164% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -212.153% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 78.575% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -16977.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -180.679% |
| Neutra Corp. | -181.24 Thousand USD | -4140.07% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 61.878% |
| PureTech Health plc | -11.62 Million USD | 33.904% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 61.875% |
| IXICO plc | -707 Thousand USD | -986.987% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 84.104% |
| CSL Limited | 4.73 Billion USD | 100.162% |
| Cellectis S.A. | -92.63 Million USD | 91.704% |